Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]- 1-piperazinyl]pyrimidine inactivates cytochrome P450 2D6 by protein adduction

Drug Metabolism and Disposition

Volumn 39, Issue 6, 2011, Pages 974-983

  Nagy, Leslie D ^a   Mocny, Catherine S ^a   Diffenderfer, Laura E ^a   Hsi, David J ^a   Butler, Brendan F ^a   Arthur, Evan J ^a   Fletke, Kyle J ^a   Palamanda, Jairam R ^b   Nomeir, Amin A ^b   Furge, Laura Lowe ^a  

^a KALAMAZOO COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 2 [4 [(2 PHENYL 1H IMIDAZOL 5 YL)METHYL] 1 PIPERAZINYL]PYRIMIDINE; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCH 66712; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HYDROXYLATION; MASS SPECTROMETRY; MOLECULAR DOCKING; MOLECULAR MODEL; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; STOICHIOMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; ESCHERICHIA COLI; HEME; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; PROTEIN BINDING; PYRIMIDINES; RECOMBINANT PROTEINS;

EID: 79956114883     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037630     Document Type: Article

References (34)

1. Baer BR, DeLisle RK, and Allen A (2009) Benzylic oxidation of gemfibrozil-1-O-β-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 22:1298-1309.
2. Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, Chauret N, Ouellet M, and Nicoll-Griffith DA (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol 17:1356-1361. (Pubitemid 39391213)
3. Chan WK, Sui Z, and Ortiz de Montellano PR (1993) Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol 6:38-45. (Pubitemid 23040370)
4. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914. (Pubitemid 34774444)
5. Correia MA and Ortiz de Montellano PR (2005) Inhibition of cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed) pp 247-322, Kluwer Academic/Plenum Publishers, New York.
6. Gillam EM, Guo Z, Martin MV, Jenkins CM, and Guengerich FP (1995) Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys 319:540-550.
7. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
8. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed) pp 377-530, Kluwer Academic/ Plenum Publishers, New York.
9. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
10. Hanna IH, Kim MS, and Guengerich FP (2001a) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch Biochem Biophys 393:255-261. (Pubitemid 32907182)
11. Hanna IH, Krauser JA, Cai H, Kim MS, and Guengerich FP (2001b) Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J Biol Chem 276:39553-39561.
12. Huey R, Morris GM, Olson AJ, and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-1152. (Pubitemid 46506716)
13. Hutzler JM, Steenwyk RC, Smith EB, Walker GS, and Wienkers LC (2004) Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H- imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol 17:174-184. (Pubitemid 38252497)
14. Islam SA, Wolf CR, Lennard MS, and Sternberg MJ (1991) A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12:2211-2219.
15. Ito Y, Kondo H, Goldfarb PS, and Lewis DF (2008) Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 26:947-956. (Pubitemid 350298014)
16. Kamel A, Obach RS, Colizza K, Wang W, O'Connell TN, Coelho RV Jr, Kelley RM, and Schildknegt K (2010) Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1B receptor antagonist elzasonan in humans. Drug Metab Dispos 38: 1984-1999.
17. Kent UM, Lin HL, Mills DE, Regal KA, and Hollenberg PF (2006) Identification of 17-α- ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 19:279-287.
18. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, and Donné-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
19. Lin HL, Zhang H, Jushchyshyn M, and Hollenberg PF (2010) Covalent modification of Thr302 in CYP2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene. J Pharmacol Exp Ther 333:663-669.
20. Marechal JD, Kemp CA, Roberts GC, Paine MJ, Wolf CR, and Sutcliffe MJ (2008) Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. Br J Pharmacol 153 (Suppl 1):S82-S89. (Pubitemid 351340994)
21. McLaughlin LA, Paine MJ, Kemp CA, Maréchal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, and Wolf CR (2005) Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol Chem 280:38617-38624. (Pubitemid 43853763)
22. Miraglia L, Pagliarusco S, Bordini E, Martinucci S, and Pellegatti M (2010) Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs. Drug Metab Dispos 38:1876-1891.
23. Moore CD, Shahrokh K, Sontum SF, Cheatham TE 3rd, and Yost GS (2010) Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity. Biochemistry 49:9011-9019.
24. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639-1662. (Pubitemid 128590223)
25. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
26. Oritz de Montellano PR and Correia MA (1983) Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu Rev Pharmacol Toxicol 23:481-503.
27. Palamanda JR, Casciano CN, Norton LA, Clement RP, Favreau LV, Lin C, and Nomeir AA (2001) Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2- phenyl-1H-imidazol- 5-yl)methyl]-1-piperazinyl]pyrimidine. Drug Metab Dispos 29:863-867. (Pubitemid 32488643)
28. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622. (Pubitemid 43847532)
29. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
30. Silverman RB (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, CRC Press, Boca Raton, FL.
31. Sridhar J, Jin P, Liu J, Foroozesh M, and Stevens CL (2010) In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem Res Toxicol 23:600-607.
32. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637. (Pubitemid 39100565)
33. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, and Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45:2116-2122. (Pubitemid 15024394)
34. Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-1018.